1:30 PM - 1:45 PM, Thursday, June 6,2019 ・ Theater 4
Founded in 2010 and based in Paris, Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancer. Invectys exploits novel approaches to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on Telomerase, the universal tumor antigen that is critical to uncontrolled cell growth, and Human Leukocyte Antigen-G (HLA-G), a critical marker of immunotolerance in cancer cell immune evasion.